<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F762A045-B727-4C4A-AC45-0115B75288AD"><gtr:id>F762A045-B727-4C4A-AC45-0115B75288AD</gtr:id><gtr:name>Clin-E-Cal Ltd.</gtr:name><gtr:address><gtr:line1>46 GRAFTON STREET</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M13 9NT</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F762A045-B727-4C4A-AC45-0115B75288AD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F762A045-B727-4C4A-AC45-0115B75288AD</gtr:id><gtr:name>Clin-E-Cal Ltd.</gtr:name><gtr:address><gtr:line1>46 GRAFTON STREET</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M13 9NT</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24930.0</gtr:offerGrant><gtr:projectCost>41550.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1F25B818-E6B7-441B-8A62-A752D9DE5119"><gtr:id>1F25B818-E6B7-441B-8A62-A752D9DE5119</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Crawford</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700565"><gtr:id>2E1520B9-03BA-40FB-920D-74E947CB0684</gtr:id><gtr:title>Rafi-tone: Market testing resubmission</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700565</gtr:grantReference><gtr:abstractText>Viral induced wheeze or chronic wheeze associated with asthma affects 5.5 million children
under 5 in Europe and the US. Our company, Clin-e-cal Ltd, has developed Rafi-tone, an
innovative device which has been created to aid compliance of young children to inhaler
medication delivered via a spacer device. Rafi-tone addresses two problems: in the short term,
the anxiety associated with the delivery of this medication; and in the longer term
maintenance of correct inhaler technique. Initially developed with a partnership between the
University of Manchester and the Central Manchester Foundation Trust (CMFT), we now
wish to evaluate the commercial viability of our novel product.
When a child develops a wheeze, delivery of inhaled medication can be a significant
challenge and can lead to substantial distress to the child and their parents. Screaming and
struggling can exacerbate the wheeze and reduce the amount of drug delivered to the child.
Clin-e-cal Ltd has developed an innovative solution which operates a simple and fun to use
educational device when the spacer is used correctly. The device is engaging, simple and
intuitive to operate for children as young as 18 months which will drive adoption. As the child
continues to use the spacer, the concern shifts from the acute problem to an ongoing concern
that the inhaler medication is actually being delivered in an effective dose and the correct
inhaler technique is maintained.
Solutions which have previously been developed to address this need have focused on novel
spacer designs, rather than creating an accessory to the patient?s existing spacer. Our
technology can be used with all of the most commonly used spacer devices and therefore will
be accessible to over 97% of current users of spacers. Our research to date leads us to believe
that Rafi-tone will be welcomed by parents and healthcare professionals, reducing a
significant source of stress during what is already a highly demanding situation.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24930</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700565</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>